The 12 closest competitors and alternatives to atai Life Sciences among biotech companies — ranked by similarity to what atai Life Sciences actually does, not by market-cap band.
Subscribe to see atai Life Sciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
atai Life Sciences is a biotech company headquartered in Germany. Its most recent funding round raised $157M in March 2021.
The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $157M | 8 named | |
| SEC Form D filing | $18.1M | — | |
| Series B | $24M | 4 named | |
| SEC Form D filing | $10.9M | — | |
| SEC Form D filing | $30.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to atai Life Sciences by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences (Therapeutics)
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Biotechnology
Reunion Neuroscience is a clinical-stage biopharmaceutical company that develops innovative therapeutics for underserved mental health disorders. Its lead drug candidate, luvesilocin, is a proprietary 5-HT2A agonist designed to provide durable antidepressant effects for patients with mood and anxiety disorders.
Biotechnology
Intra-Cellular Therapies was a U.S. biopharmaceutical company focused on developing treatments for central nervous system disorders. Its principal product, CAPLYTA (lumateperone), is used to treat schizophrenia and depressive episodes associated with bipolar disorder in adults, serving patients and mental-healthcare providers.
Biotechnology
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Similar biotech company
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Biotechnology
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Similar biotech company
Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic medicines for psychiatric and neurological disorders. Its programs have included BPL-003, an intranasal formulation of 5-MeO-DMT, intended for conditions such as treatment-resistant depression and alcohol use disorder.
Biotechnology
Lykos Therapeutics is a biotechnology company developing psychedelic-assisted therapies, particularly MDMA-assisted therapy for post-traumatic stress disorder (PTSD). It works with clinicians and researchers to advance regulated treatments for people with PTSD and related mental-health conditions.
Similar biotech company
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Biotechnology
Serenatis Bio is a biotechnology company founded in 2024 and headquartered in Cambridge, United Kingdom. It is developing novel, precision therapeutics for obsessive-compulsive disorder (OCD).
Biotechnology
Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Similar biotech company
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for atai Life Sciencesand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →